Levodopa-induced dyskinesia: Clinical features, pathophysiology, and medical management
Authors:
Open Access
- 1 January 2017
- journal article
- research article
- Published by Medknow in Annals of Indian Academy of Neurology
- Vol. 20 (3) , 190-198
Abstract
Dyskinesia, wearing-off or off-period dyskinesia, and diphasic dyskinesia. Pathogenesis of LID is complex, and different neurotransmitters such as dopamine, glutamine, adenosine, and gamma-aminobutyric acid play important role altering the normal physiology of direct and indirect pathway of cortico-basal ganglia-thalamic loop responsible for fine motor control. Treatment of LID requires careful history taking and clinical examination to find the type of dyskinesia as different approach is required for different types. Changes in dopaminergic medication including continuous dopaminergic stimulation are very helpful in the management of peak-dose dyskinesia. Different types of surgical approaches including unilateral pallidotomy and deep brain stimulation have given very good result in patients, who cannot be managed by medications alone. The surgical management of LID is dealt with in detail in another review in this series....Keywords
This publication has 75 references indexed in Scilit:
- Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributionsMovement Disorders, 2015
- Improvement of dyskinesias withl-dopa infusion in advanced Parkinson's diseaseActa Neurologica Scandinavica, 2015
- New treatments for the motor symptoms of Parkinson’s diseaseExpert Review of Clinical Pharmacology, 2014
- Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)Neurology, 2012
- The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's diseaseMovement Disorders, 2011
- Effects of a Dopamine Agonist on the Pharmacodynamics of Levodopa in Parkinson DiseaseArchives of Neurology, 2010
- Histamine H3 receptor agonists reduceL‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson's diseaseMovement Disorders, 2006
- Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaqueEuropean Journal of Pharmacology, 2004
- Dyskinesias and motor fluctuations in Parkinson's diseaseBrain, 2000
- The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled StudyClinical Neuropharmacology, 2000